

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Benralizumab with corticosteroids for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis ID6266

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
AstraZeneca (benralizumab)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	
Asthma + Lung UK	
Cardiac Risk in the Young	 Board of Community Health Councils in Wales
EOS Network	British National Formulary
Genetic Alliance UK	Care Quality Commission
Kidney Care UK	Department of Health, Social Services
Kidney Research UK	and Public Safety for Northern Ireland
Lauren Currie Twilight Foundation	Healthcare Improvement Scotland
Lupus UK	Hospital Information Services –
National Kidney Federation	Jehovah's Witnesses
National Rheumatoid Arthritis Society	Medicines and Healthcare products
South Asian Health Foundation	Regulatory Agency
Specialised Healthcare Alliance	National Association of Primary Care
Vasculitis UK	National Pharmacy Association
Versus Arthritis	NHS Confederation
	Scottish Medicines Consortium
Healthcare professional groups	Welsh Government
Association for Respiratory	Welsh Health Specialised Services
Technology and Physiology	Committee
 Association of Respiratory Nurse 	
Specialists	Possible comparator companies
 British Association for Paediatric 	None
Nephrology	
British Association of Dermatologists	Relevant research groups
British Association of Urological	British Society for Dermatological
Nurses	Surgery
British Association of Urological	British Skin Foundation Degree at words
Surgeons	Dermatrust Cachrana Skin Croun
British Dermatological Nursing Group	Cochrane Skin Group Conomics England
British Geriatrics Society	Genomics England MRC Clinical Trials Unit
British Society for Paediatric and Adalage and Phase parts in the second Phase parts in th	
Adolescent Rheumatology	National Institute for Health Research Skip Treatment and Because Trust
British Society for Rheumatology	Skin Treatment and Research Trust

Provisional stakeholder list for the evaluation of benralizumab with corticosteroids for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis ID6266 Issue date: July 2024



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 British Thoracic Society Health Lumen Immunodeficiency UK Primary Care Dermatology Society Primary Care Respiratory Society UK Primary Care Rheumatology and Musculoskeletal Medicine Society Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine Society for DGH Nephrologists Society of Vascular Nurses UK Clinical Pharmacy Association UK Renal Pharmacy Group Urology Foundation 	UK and Ireland Vasculitis Rare Disease Group Associated Public Health groups Public Health Wales UK Health Security Agency
OthersDepartment of Health and Social CareNHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

<u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Provisional stakeholder list for the evaluation of benralizumab with corticosteroids for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis ID6266 Issue date: July 2024



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.